News FDA OKs Satralizumab (Enspryng) for NMOSD by Medscape • 2020/08/17 • 0 Comments Satralizumab is a humanized monoclonal antibody that inhibits interleukin-6 receptor activity, believed to play a key role in the inflammation associated with NMOSD. FDA Approvals Full Story →